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ABSTRACT
Paracetamol is a common analgesic and
antipyretic drug for management of fever and
mild-to-moderate pain in infants and children,
and it is considered as first-line therapy for the
treatment of both according to international
guidelines and recommendations. The
mechanism of action of paracetamol is
complex and multifactorial, and several
aspects of the pharmacology impact its clinical
use, especially in the selection of the correct
analgesic and antipyretic dose. A systematic
literature search was performed by following
procedures for transparent reporting of
systematic reviews and meta-analyses. To
maximize efficacy and avoid delays in effect,
use of the appropriate dose of paracetamol is
paramount. Older clinical studies using
paracetamol at subtherapeutic doses of
B10 mg/kg generally show that it is less
effective than non-steroidal anti-inflammatory
drugs (NSAIDs). However, recent evidence
shows that when used at dose of 15 mg/kg for
fever and pain management, paracetamol is
significantly more effective than placebo, and at
least as effective as NSAIDs. Paracetamol 15 mg/
kg has a tolerability profile similar to that of
placebo and NSAIDs such as ibuprofen and
ketoprofen used for short-term treatment of
fever. However, when used at repetitive doses
for consecutive days, paracetamol shows lower
risk of adverse events compared to NSAIDs.
Also, unlike NSAIDs, paracetamol is indicated
for use in children of all ages. Overall, clinical
evidence qualifies paracetamol 15 mg/kg a safe
and effective option for treatment of pain and
fever in children.
Keywords: Antipyretic; Child; Fever; Pain;
Paracetamol; Safety
INTRODUCTION
Fever and pain occur frequently in infants and
children [1]. Management of fever tends to be
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characterized by over-treatment, because of the
parents anxiety and fever phobia [2–6], whereas
management of pain is characterized by
under-treatment, particularly in very young
children with acute painful injuries [7, 8].
Paracetamol is a common analgesic and
antipyretic drug for management of fever and
mild-to-moderate pain in pediatric patients. It is
the first-line choice for the treatment of both
fever and pain according to national and
international guidelines and recommendations
and it is also included in the List of Essential
Medicines for Children of the World Health
Organization (WHO) [9–20].
Appropriate dosages should be used to
ensure optimal efficacy and safety of
paracetamol [18]. Given the wide range of
body weight across children of different ages,
guidelines for treatment of pain highlight the
importance of administering the correct dose
according to body weight, hence the use of
milligram per kilogram (mg/kg) dosing [10, 12,
14, 15, 18]. Pediatric patients, especially if they
have fever or pain, are acutely unwell may be
frightened and less co-operative than usual [21].
Flexible formulations should guarantee the ease
of administration and aid dosing accuracy.
Specific oral formulations of paracetamol, as
syrup and drops, should be recommended
because easy to administer and because they
allow selection of the right mg/kg dose.
Paracetamol recommended doses vary from 10
to 15 mg/kg every 4–6 h (up to 60 mg/kg/day)
[9, 14, 18, 22]. A common issue is the variability
of dosages used to treat fever and pain in
clinical practice, where paracetamol doses
range from 5 to 20 mg/kg [9, 23–25]. Studies
have shown that dose variability can depend on
to the specialty of the prescribing physician,
with pediatricians prescribing more
suitable doses than family physicians or
otolaryngologists [23].
Clinical trials have investigated different
doses, with older trials focusing on doses
\10 mg/kg, now known to be subtherapeutic
[26–33]. More recent studies have investigated
higher oral paracetamol doses 10–30 mg/kg
[34–40] and the available evidence now
suggests that 15 mg/kg could be the optimal
dose.
The objective of this article was to review the
literature and identify the analgesic and
antipyretic doses of paracetamol that
guarantee efficacy and safety in children. This
article is based on previously conducted studies
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
METHODS
A systematic literature search was performed in
Medline using the search terms [‘‘pain’’ OR
‘‘fever’’ OR ‘‘migraine’’] AND ‘‘child’’ AND
‘‘acetaminophen’’ (paracetamol) AND [‘‘dose’’
or ‘‘dosing’’ or ‘‘dosage’’ or ‘‘dose-related’’],
both as subject headings and keywords. Papers
with acetaminophen indexed as adverse effect,
contraindication, metabolism,
pharmacokinetics, pharmacology, therapeutic
use, and toxicity were selected. No restrictions
were applied to the other search terms. The
search was limited to children with no date or
other limits applied. The search results were
de-duplicated and papers relevant to this review
were selected manually. Other supporting
references were sourced by specific literature
searches as required, or were obtained from
bibliographies of review articles or from the
authors’ personal libraries.
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RESULTS OF LITERATURE SEARCH
A total of 114 papers were found. Of these, 53
papers explicitly mentioning mg/kg dosing of
paracetamol were manually selected for
potential inclusion in this review. Of these, 14
were review articles, 4 were pharmacokinetic
(PK)/pharmacodynamics (PD) studies, 2 were
meta-analyses of clinical trials, and 23 were
clinical studies of paracetamol in children
either as the only arm or as one of the study
arms (21 specifically studied paracetamol
15 mg/kg and 2 studied paracetamol 12 mg/
kg). Papers reporting trials of 10 mg/kg or lower
doses were included for comparative purposes,
but are not discussed in depth.
PHARMACOLOGY
Pharmacokinetics
Paracetamol is a highly lipid-soluble compound
that is readily absorbed through the gut [time to
peak drug concentration (Tmax) 0.5–0.75 h after
oral administration], with a bioavailability of
nearly 90% [41–43]. It has a pKa of 9.5 and is
therefore highly polarized in the stomach with
very low gastric absorption [44]. Once in the
basic environment of the duodenum,
paracetamol rapidly crosses the mucosa and
enters the bloodstream. Paracetamol shows a
negligible binding to plasma proteins (10–25%),
a key feature that differentiates it from other
analgesics/antipyretics such as ibuprofen [24,
42]. Paracetamol is metabolized principally in
the liver. In adults, glucuronide and sulfate
conjugates account for 50–60% and 25–30%,
respectively, and\10% remain unmodified. In
children, though the metabolic pathways are
the same, their relative contributions change
with age, since the sulfation pathways are
mature at birth while the glucuronidation
pathways matures in about 2 years [24, 41].
Almost 90% of paracetamol metabolites are
excreted into the urine within 24 h [24].
Paracetamol half-life (t) is short, ranging from
2 to 2.5 h [41].
A key issue when dealing with paracetamol
pharmacology is the ‘‘effect compartment’’
concept that explains the time delay between
therapeutic levels of paracetamol in the plasma
and analgesic or antipyretic effect [24, 45]. The
therapeutic effect of paracetamol is not linearly
related to plasma concentration. Both
antipyresis and analgesia are related to
concentrations reached in the brain, with
paracetamol needing to exit the bloodstream
and reach the neural tissue before exerting its
effects [24]. This effect compartment model has
key clinical implications, both for dosing levels
and dosing schedules.
The administered dosage influences the
speed of onset of action and the achieved
plasma concentrations, so that appropriate
dosing to achieve suitable effect compartment
concentrations is crucial for maximum efficacy
[45].
Pharmacodynamics
The mechanism of action of paracetamol is still
debated. It was first hypothesized that the drug
exerts its effect via inhibition of prostaglandin
synthesis by cyclooxygenase (COX); it is now
known that paracetamol has several PD targets
within the brain. Paracetamol inhibits COX and
reduces prostaglandin synthesis, with an
interaction site different from that of
non-steroidal anti-inflammatories (NSAIDs)
[46, 47]. NSAIDs inhibit prostaglandin
synthesis by competing with arachidonic acid
for the COX binding site, whereas paracetamol
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reduces prostanoid formation by acting at the
peroxidase site [46, 47]. More precisely,
paracetamol is thought to act as a reduction
factor, donating electrons to the radical Fe4?
within the COX peroxidase site, thereby
preventing the generation of tyrosine radials
and, in turn, preventing arachidonic acid
oxygenation [47]. Due to the large amounts of
hydroperoxide present in inflammatory
environments [48], the activity of paracetamol
is diminished because cellular hydroperoxide
oxidizes the radical Fe within the peroxidase
site, preventing the effect that paracetamol has
on arachidonic acid oxygenation [47].
Generally, hydroperoxide is present in large
amounts in inflammatory environments,
reducing paracetamol activity.
These findings explain why paracetamol
cannot counteract inflammation and platelet
aggregation, as well as its exclusive central
nervous system (CNS) activity [24]. Several
lines of evidence demonstrate that the ability
of paracetamol to reduce fever is due to
inhibition of hypothalamic prostaglandin
formation [24]. Fever occurs when
warm-sensitive neurons, normally responsible
for triggering heat loss, are inhibited by
prostaglandins, mainly prostaglandin E2
(PGE2) [20]. By inhibiting COX in neural and
brain endothelial cells, paracetamol counteracts
PGE2 formation, thereby relieving suppression
of warm-sensitive neurons that are then free to
reset thermoregulation toward lower body
temperature [49]. Therefore, mechanism of
antipyresis by paracetamol occurs through the
canonical inhibition of COX within the CNS,
akin to that exerted by classic NSAIDs.
The mechanisms of the analgesic effect of
paracetamol differ from that of NSAIDs. Several
lines of evidence indicate that in addition to
COX inhibition, the descending, serotonergic
pain control system is also associated with
paracetamol analgesia [24, 47]. This occurs via
indirect activation of serotonin receptors,
including the 5 hydroxytryptamine3 (5HT3)
subtype, on opioidergic interneurons that, in
turn, reduce excitability of dorsal horn neurons
projecting to the thalamus [21]. Accordingly,
the 5HT3 receptor antagonists tropisetron or
granisetron completely prevent analgesia
prompted by 1 g oral paracetamol [50, 51]. An
additional mechanism through which
paracetamol prompts analgesia might be its
transformation into
N-arachidonyl-aminophenol (also called
AM404) by fatty acid hydrolase, an enzyme
highly expressed within the brain. AM404
activates TRPV1 on terminal of nociceptors,
but also inhibits COX1-2, and favors
cannabinoid receptor-1 (CB1)-dependent
analgesia by counteracting cellular uptake of
the endogenous CB1 receptor agonist
anandamide [24, 47].
ANTIPYRESIS BY PARACETAMOL:
PHARMACOLOGY-BASED
PRACTICAL IMPLICATIONS
Due to indisputable ethical reasons, repetitive
cerebrospinal fluid (CSF) sampling cannot be
obtained in children for research. As a
consequence, maximal antipyretic effects
(Emax) or the plasma/CSF concentration
producing half of Emax (EC50) are merely
estimated from empirical data deriving from
specific assessments. PK studies of paracetamol
report an Emax of 3 C and a plasma EC50 of
9.7 mg/L obtained with classic doses of
10–15 mg/kg [52, 53]. Although evidence
suggests that paracetamol 10–12.5 mg/kg is
effective at antipyresis in children, as
mentioned above there is a delay between the
achievement of appropriate paracetamol
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concentrations and onset of action [24]. This
time delay is a key aspect of practical treatment
of fever in children, so augmenting the dose or
selecting the highest dose is most likely to
provide the onset and duration of action
necessary for clinical improvement. Gibb and
Anderson [45] suggested that increasing the
paracetamol dose would speed up onset of
antipyresis. A recent analysis of data from
3155 feverish children receiving paracetamol
in 53 studies partly confirms Gibb and
Anderson estimation [25].
Temple et al. [25] also showed that 15 mg/kg
produced a larger relative temperature
reduction and a longer duration of substantial
temperature reduction compared with 10 mg/
kg. After 30 min, 15 mg/kg paracetamol
decreased body temperature by 0.71 C, while
10 mg/kg paracetamol reduced body
temperature by 0.36 C (i.e., only 0.4 C higher
than that achieved with the lower dose).
However, duration of antipyresis was
substantially longer with the dose of 15 mg/kg.
15 mg/kg oral paracetamol was associated with
a mean temperature reduction of about 1 C
greater than that observed with the 10 mg/kg
dose after 8 h (-1.35 vs. -0.65 C change in
temperature with 15 and 10 mg/kg at 8 h,
respectively) [25]. A review summarizing
available PK/PD (fever reduction) data of oral
paracetamol in children aged 6 months to
12 years concluded that the antipyretic effect
of paracetamol is dose dependent [22]. In the
dose range of 10–15 mg/kg, paracetamol was
more effective than placebo in this analysis.
Variables such as the initial temperature and the
age of the patient can influence the antipyretic
response of paracetamol [42]. Taken together,
data indicate that 15 mg/kg, allowing an earlier
onset and a longer duration of effect is an
optimal, oral paracetamol dose for an
antipyretic effect.
ANALGESIA BY PARACETAMOL:
PHARMACOLOGY-BASED
PRACTICAL IMPLICATIONS
The molecular mechanisms responsible for
fever reduction and analgesia by paracetamol
differ substantially. The pleiotypic mechanisms
of paracetamol-induced analgesia have
important consequences in determining the
correct use of this drug for the efficient
treatment of pain. A key aspect of paracetamol
analgesia is that it occurs at CNS drug
concentrations higher than those required for
antipyresis [24]. Specifically, it has been
reported that plasma EC50 of antipyresis
(4.63 mg/L) is almost half of that of analgesia
(9.98 mg/L) [45].
Although the pharmacological basis of the
higher plasma EC50 required to treat pain still
needs to be unequivocally determined, it is
conceivable that it is mainly related to the
various mechanisms of paracetamol analgesia.
Indeed, it is plausible that the drug must reach
CNS concentrations higher than those able to
inhibit COX to fully activate the
pain-suppressing effect on opioid receptor and
descending serotonergic pathway. These
different PD features translate into different
therapeutic approaches in the clinical setting,
altering the practical use of the drug when
treating fever or pain in children to obtain
maximal therapeutic benefit.
The time delay caused by the effect
compartment must also be taken into account
when choosing an appropriate dose of
paracetamol, since there is a threshold
concentration required in the CNS before
analgesic activity is produced, and
under-dosing results in a delay in pain
reduction. The minimum target effect
compartment concentration is 11.8 mg/L for
pain relief in children. At least 15 mg/kg is
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required orally to achieve analgesic paracetamol
levels [54]. The possible time delay should also
drive the choice of time interval between
repeated doses, so that appropriate steady-state
plasma levels are reached in a timely manner.
Unfortunately, the time–concentration
relationship has not been determined after
multiple paracetamol dosing. However, it is
possible to extrapolate such a relationship by
analyzing data from the literature. Specifically,
evidence that a dose of 15 mg/kg in adults leads
to a peak drug concentration (Cmax) of 11.8 mg/
L [55, 56], together with the notion that in the
plasma concentrations increase linearly with
dose, allows an estimation of a Cmax of 12.6 mg/
L following a dose of 15 mg/kg. This
information along with that provided by the
study by Hopkins et al. [57] which showed
plasma Tmax and t, respectively, of 114 and
138 min in children receiving 15 mg/kg of oral
paracetamol means an approximate
time/concentration relationship describing
plasma values in children can be constructed
(Fig. 1). To determine this relationship
following multiple oral doses of 15 mg/kg, the
data from the study by Nahata et al. [58], which
reported a 13.35% plasma accumulation at the
steady state in children receiving this dose in a
repetitive dosing paradigm, can be employed.
Combining these PK parameters produces a
time/plasma concentration curve after
repetitive (every 6 h) 15 mg/kg oral dosing
(Fig. 2). This estimation indicates that steady
state of plasma concentrations of 14.28 mg/L is
reached within 20 h after initiating repetitive
dosing. Remarkably, steady-state
concentrations of 14.28 mg/L are above the
pain threshold of 11 mg/L identified by the
study by Brett and colleagues [54]. These
extrapolations suggest that oral dosing of
paracetamol at 15 mg/kg every 6 h permits
rapid achievement of steady-state
concentrations and Cmax well above those
required to prompt analgesia. Still, to expedite
onset of pain resolution, adoption of a loading
dose will obviously shift the
time–concentration curve depicted in Fig. 1
upward, thereby allowing faster attainment of
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steady state. Remarkably, these data, based both
on empirical findings and estimations, nicely fit
with guidelines proposed by different
institutions: that regimens of 15 mg/kg oral
paracetamol every 6 h provide efficient pain
control in children [14].
CLINICAL MANAGEMENT OF FEVER
WITH PARACETAMOL
The pharmacological treatment of fever in
children and infants should be carried to
reduce the discomfort of the child, not to fight
fever per se. Frequently, fever in children causes
anxiety in the parents that if not properly
managed can lead to mistakes, even in the
choice of medication and the appropriate dose.
In general, paracetamol is the only
antipyretic approved for use in children from
birth and it is indicated as the drug of choice in
pediatric guidelines for the management of
fever in children [13, 15]. Unlike ibuprofen,
which is approved for use in children over
3 years of age, paracetamol is indicated in
patients with chickenpox and in those with
dehydration and pneumonia [13, 14].
Clinical Trial Data
Clinical data for 15 mg/kg paracetamol in
children with fever are summarized in Table 1.
These studies investigated paracetamol
12–15 mg/kg vs. ibuprofen [34, 35, 40, 59, 60],
ketoprofen [59], dipyrone [40], and placebo [38,
61]. Compared with ibuprofen and ketoprofen,
paracetamol 15 mg/kg had a comparable
efficacy [34, 35, 40, 59, 60]. Dipyrone was
more effective than paracetamol at
temperature normalization and temperature
reduction [40]. Compared with placebo,
paracetamol showed a better efficacy profile
[38, 61]. Ibuprofen, ketoprofen and dipyrone
used for short term had similar safety profile to
paracetamol [34, 35, 40, 59, 60] that in turn
shows a similar or better tolerability profile to
placebo (Table 1) [38, 61].
Other studies have shown similar results. A
recent systematic review of clinical data showed
that the 10–15 mg/kg oral dose first
recommended in 1983 is still appropriate for
the treatment of fever in children [25].
However, as mentioned above, the same
review also showed data in which 15 mg/kg
paracetamol was better at reducing temperature
for longer time than 10 mg/kg paracetamol, the
mean maximum temperature decrease from
baseline was 1.17 C in the 10 mg/kg studies
and 1.60 C in the 15 mg/kg studies, and the
temperature decrease from baseline at 480 min
was 0.65 C in the 10 mg/kg studies and 1.35 C
in the 15 mg/kg studies [25]. These results are
supported by additional clinical trials of 10 mg/
kg, paracetamol which generally was
consistently less effective than ibuprofen
[27–29, 62]. The importance of choosing the
right dose of paracetamol to treat fever should
be strongly stressed, since a low dose could
compromise effectiveness, and physicians
should carefully choose the dose of
paracetamol guaranteeing antipyretic efficacy
and safety in children. The clinical trial data
presented suggest that paracetamol 15 mg/kg is
the most appropriate choice for rapid and
effective fever reduction.
CLINICAL MANAGEMENT OF PAIN
WITH PARACETAMOL
In children with pain and headache, the
recommended dose of paracetamol is
10–15 mg/kg administered 3–4 times a day to
a maximum dose of 60 mg/kg/day [18, 19]. The
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most appropriate medication for the treatment
of pain should be chosen based on the
underlying cause of the pain. Options include
NSAIDs and paracetamol. Paracetamol is not
recommended for anti-inflammatory use [63];
however, it is the most appropriate drug in
children with pain of a non-inflammatory
etiology [15, 18]. A systematic review
investigated paracetamol as an opioid-sparing
treatment in children with perioperative pain
[64]. While the results were mixed, with
paracetamol allowing for opioid sparing in
some studies but not others, the authors
acknowledged that the variability in
effectiveness may have been due to inadequate
paracetamol dosing and variable absorption
seen with rectal paracetamol, and stressed the
importance of appropriate paracetamol dosing
and route of administration [64].
Clinical Trial Data
Clinical data for paracetamol 15 mg/kg in
children with pain are summarized in Table 2.
Paracetamol has been compared with ibuprofen
[39, 65–68], ketoprofen [69], naproxen [70], and
codeine [66] in this setting. Studies of the use of
paracetamol in pain show that paracetamol is
generally as effective as ibuprofen, naproxen,
and ketoprofen in reducing pain [39, 65, 69,
70]. In two studies, there was a significant
difference between paracetamol and ibuprofen,
with one study favoring ibuprofen [66], and one
favoring paracetamol [68] (Table 2). Also, when
used a single agents, paracetamol was as
effective as codeine at reducing pain caused by
musculoskeletal injury [66]. Generally,
paracetamol was more effective than placebo
at reducing pain [39, 68, 69]. In the treatment of
migraine, both paracetamol and ibuprofen were
more effective than placebo at reducing
headache pain [67]. As for the clinical trials in
fever, the tolerability of paracetamol was similar
to that of ibuprofen, naproxen, ketoprofen,
used for short-term treatment, and placebo
(Table 2).
A systematic review of 17 clinical trials
showed that single-dose paracetamol 7–15 mg/
kg had similar analgesic effect to ibuprofen
4–10 mg/kg in moderate to severe pain [71].
Similarly, a systematic review of 10 clinical trials
in the use of paracetamol 15 mg/kg to treat
migraine showed that paracetamol is as
effective as ibuprofen and nimesulide at
reducing migraine symptoms, and more
effective than placebo with a similar
tolerability profile [72].
TOLERABILITY AND SAFETY
The WHO has highlighted the need for
long-term safety data for paracetamol and
ibuprofen [18]. The adverse event profile of
paracetamol vs. active comparators and placebo
in the treatment of fever and pain and migraine
is outlined in detail in Tables 1 and 2.
Generally, the adverse events associated with
paracetamol were of similar or lesser frequency
than active comparators; in some cases,
paracetamol recipients had similar levels of
AEs to NSAIDs [34, 70] but in most cases the
incidence of general AEs was lower [40, 65, 66].
NSAIDs typically had a higher incidence of
gastrointestinal AEs than paracetamol, and the
same also occurs even when they are used for
short term [34, 40, 59, 65].
Generally, paracetamol is a very safe drug
that is used extensively for the treatment of
fever and pain worldwide. Government body
guidelines state that paracetamol is safe for use
throughout pregnancy; indeed, Italian
authorities have designated it as the drug of
choice for pain relief when administered at
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therapeutic doses (\3 g/day) to pregnant
women. Data suggests that paracetamol use
during pregnancy does not result in congenital
anomalies, and it is not contraindicated during
breastfeeding. Furthermore, paracetamol can be
effective in the management of ductus
arteriosus in neonates, achieving high rates of
ductal closure in the absence of adverse events
[73]. While there may be an increased risk of
asthma and behavioral issues such as
attention-deficit disorder with paracetamol use
in pregnancy, these results have yet to be
confirmed and are likely subject to
confounding factors [74]. The association may
be a consequence of reverse causality bias [75]
or the influence of respiratory tract infections
during pregnancy [76, 77].
Paracetamol toxicity can result in cases of
overdose or where there are underlying
conditions present [78]. As with any drug, care
must be used when administering paracetamol
to children who may be suffering from
dehydration [79], malnutrition, or receiving
concomitant medications [18]. Chronic
overdosing of paracetamol is linked to hepatic
injury prompted by the paracetamol metabolite
N-acetyl benzoquinone (NAPQI) and
necessitates prompt N-acetylcysteine treatment
[9], however, severe liver injury with short
courses of supratherapeutic doses is rare [80].
Toxicity in children tends to occur after
administration of single doses ranging from
120 to 150 mg/kg (Fig. 3), which is 10–15 times
the recommended dosage [78], even though
idiosyncratic reactions associated to increased
activity of the hepatic cytochrome P450
detoxifying system have been reported [85].
Sustained dosing ([1 day) with[90 mg/kg/day
(whereas the recommended dosing 60 mg/
kg/day) puts children aged \2 years at high
risk for hepatotoxicity [81]. Case reports
describe children presenting with paracetamol
toxicity after sustained dosing of 100–367 mg/
kg/day [81]. A recent study conducted in
Australia and New Zealand revealed that
hepatic failure due to paracetamol ingestion
occurred in children mostly as a result of
medication errors such as doses in excess of
120 mg/kg/day, double dose, too frequent
administration, coadministration of other
medicines containing paracetamol or regular
paracetamol for up to 24 days [82]. Also, as far as
the potential risk of asthma and allergy in
children treated with paracetamol is
concerned, a clear causative role still needs to
be unequivocally demonstrated because the
initial paracetamol use–asthma incidence
association [86] has been recently diminished
by considering respiratory tract infection as a
confounding factor [87]. Finally, results from
recent clinical trials indicate that prophylactic
use of paracetamol to prevent febrile reactions
after immunization is not indicated because of
the risk of reduced immunoglobulin production
[88].
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Fig. 3 Time–concentration relationship after multiple
paracetamol 15 mg/kg oral doses. Oral paracetamol
15 mg/kg every 6 h allows achievement of analgesic plasma
concentrations well beneath (about tenfold) those induc-
ing toxicity
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CONCLUSIONS
Due to the pharmacology of paracetamol, it is
important to choose an appropriate dose to get
maximum efficacy while minimizing adverse
effects. In children, paracetamol 15 mg/kg is the
appropriate dose to use for treatment of fever.
In the treatment of pain in children, the
minimum dose of paracetamol that should be
used is 15 mg/kg. According to WHO
guidelines, the only available option for pain
management in children below 3 months of age
is paracetamol; the 10 mg/kg dose every 4–6 h
should be recommended in this case [18]. For
the effective control of pain, paracetamol
should be given as a scheduled dose over time,
and not administered at need. The correct dose
of paracetamol provides effective treatment of
pain and fever that is equivalent to that seen
with NSAIDs, making it an effective and safer
treatment option in this setting.
Only paracetamol and ibuprofen appear
recommended for reduction of fever in
children [15]. It is not recommended to use
them in combination or alternating
paracetamol and ibuprofen. Also, whereas
ibuprofen is not approved for use in children
under three months of age and is
contraindicated in patients with chickenpox
and in those with dehydration and pneumonia,
paracetamol can be used from birth and in
patients with dehydration [13, 14]. As for
analgesia in children suffering from
mild-to-moderate pain, paracetamol appears
the drug of choice with an optimal dosage of
15 mg/kg every 4–6 h (no more than 4 times per
day) [83]. Of note, paracetamol is also the drug
of choice for the treatment of mild-to-moderate
pain in neonates [83]. Finally, to avoid toxicity
only standard doses should be used, with doses
calculated according to weight and age;
attention must also be paid to any clinical
factors or concomitant medications that may
increase the risk of toxicity.
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